"Capecitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
| Descriptor ID |
D000069287
|
| MeSH Number(s) |
D03.383.742.680.245.500.425 D03.383.742.698.875.404.425 D13.570.230.329.313 D13.570.685.245.500.425
|
| Concept/Terms |
Capecitabine- Capecitabine
- N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
|
Below are MeSH descriptors whose meaning is more general than "Capecitabine".
Below are MeSH descriptors whose meaning is more specific than "Capecitabine".
This graph shows the total number of publications written about "Capecitabine" by people in this website by year, and whether "Capecitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Capecitabine" by people in Profiles.
-
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 2019 05; 22(3):577-586.
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
-
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. Breast Cancer Res Treat. 2013 May; 139(1):135-43.
-
Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair (Amst). 2008 Feb 01; 7(2):162-9.
-
Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol. 2003 Nov; 65(2):167-72.